Table 1.
Effects of single and combined treatment with systemic S-PBN or l-NAME and intraocular BDNF on RGC survival 14 days after optic nerve transection in the adult rat
| 1/6 Retinal radius | 3/6 Retinal radius | 5/6 Retinal radius | Average | |
|---|---|---|---|---|
| Normal control | 2647 ± 95 | 2289 ± 53 | 1180 ± 46 | 2039 ± 56 (n = 11) |
| Axotomy w/o th. | 409 ± 50 | 354 ± 56 | 254 ± 49 | 339 ± 43 (n = 6) |
| Vehicle | 587 ± 75 | 394 ± 90 | 255 ± 77 | 412 ± 77 (n = 4) |
| S-PBN 100 | 402 ± 72 | 271 ± 37 | 228 ± 27 | 300 ± 45 (n = 6) |
| S-PBN 200 | 336 ± 18 | 254 ± 7 | 196 ± 13 | 262 ± 9 (n = 6) |
| l-NAME 25 | 485 ± 43 | 433 ± 31 | 340 ± 27 | 419 ± 27 (n = 4) |
| BDNF 200 | 906 ± 83* | 621 ± 76** | 355 ± 36 | 627 ± 60** (n = 5) |
| BDNF 200 + S-PBN 100 | 1531 ± 150**,*** | 943 ± 95**,*** | 486 ± 59** | 987 ± 94**,*** (n = 5) |
| BDNF 500 | 1253 ± 138* | 777 ± 80* | 382 ± 61 | 804 ± 87* (n = 7) |
| BDNF 500 + S-PBN 100 | 1988 ± 175**,*** | 1624 ± 167**,**** | 868 ± 74**,**** | 1493 ± 123**,**** (n = 9) |
| BDNF 2000 | 1103 ± 187** | 749 ± 88** | 392 ± 26 | 748 ± 96** (n = 4) |
| BDNF 2000 + S-PBN 100 | 1409 ± 235** | 1147 ± 197** | 687 ± 130*,*** | 1081 ± 169** (n = 4) |
| BDNF 500 + l-NAME 25 | 1634 ± 27*,*** | 1297 ± 83*,*** | 881 ± 14*,*** | 1270 ± 35*,*** (n = 3) |
Data are given as mean RGC densities (cells per square millimeter) ± SEM at one-sixth, one-half, and five-sixths of the retinal radius and averaged over the radius. axo w/o th., Axotomy without treatment. S-PBN,N-tert-butyl-(2-sulfophenyl)-nitrone at doses of 100 and 200 mg/kg twice daily. l-NAME:N-ω-nitro-l-arginine-methylester at a dose of 25 mg/kg twice daily. BDNF, Brain-derived neurotrophic factor at doses of 200, 500, and 2000 ng/injection. For statistical analysis, the Mann–Whitney U test for independent samples was used.
*,**Significant differences from axo w/o th. (*p < 0.05; **p < 0.01).
***,****Significant differences from single BDNF treatment (***p < 0.05; ****p < 0.01, respectively).